Relypsa Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 400

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.48B

  • Investors
  • 1

Relypsa General Information

Description

Operator of a biopharmaceutical company based in Redwood City, California. The company is focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are overlooked and undertreated and can be addressed in the gastrointestinal tract.

Contact Information

Website
www.relypsa.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Acquirer
Galenica Group
Corporate Office
  • 100 Cardinal Way
  • Redwood City, CA 94063
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Relypsa Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 01-Sep-2016 $1.48B 00000 00.000 Completed Profitable
10. Debt - General 03-May-2016 00000 00000 Completed Profitable
9. Secondary Transaction - Open Market 31-Mar-2016 00000 Completed Generating Revenue
8. Secondary Transaction - Open Market 31-Mar-2015 00000 Completed Generating Revenue
7. Debt - General 02-Jun-2014 0000 00000 Completed Profitable
6. Secondary Transaction - Open Market 17-Apr-2014 00000 Completed Generating Revenue
5. IPO 15-Nov-2013 000.00 00000 00000 Completed Profitable
4. Later Stage VC (Series C) 15-Aug-2012 0000 00000 00000 Completed Profitable
3. Early Stage VC (Series B2) 28-Jul-2011 $35M $113M 00000 Completed Profitable
2. Early Stage VC (Series B1) 07-Sep-2010 $35M $78M 0000 Completed Profitable
To view Relypsa’s complete valuation and funding history, request access »

Relypsa Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.00
Series C-1 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B-2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-1 55,377,880 $0.001000 8% $1 $1 1x $1 11.2%
Series A 55,377,880 $0.001000 8% $1 $1 1x $1 11.2%
To view Relypsa’s complete cap table history, request access »

Relypsa Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company based in Redwood City, California. The company is focused on the discovery, deve
Biotechnology
Redwood City, CA
400 As of 2016
00000
0.000 0000-00-00
000000&0 00000

000000

tion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
0000000000000
Wayne, PA
000 As of 0000
00000
000000000 00000

000000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad mi
0000 000000000
San Diego, CA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Relypsa Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aclaris Therapeutics Formerly VC-backed Wayne, PA 000 00000 000000000 00000
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA 000 00000 000000000 00000
Rhythm Pharmaceuticals Formerly VC-backed Boston, MA 000 00000 000000000 00000
Zealand Pharma Formerly VC-backed Soborg, Denmark 000 00.000 000000000 00.000
Heron Therapeutics Formerly VC-backed San Diego, CA 000 00000 000000000 00000
You’re viewing 5 of 18 competitors. Get the full list »

Relypsa Patents

Relypsa Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2874633-A4 Compositions comprising crosslinked cation-binding polymers Inactive 19-Jul-2012 000000000 0
CA-2879425-A1 Compositions comprising crosslinked cation-binding polymers Inactive 19-Jul-2012 000000000
GB-201502802-D0 Compositions comprising crosslinked cation-binding polymers Active 19-Jul-2012 000000000
DE-112013003596-T5 Compositions comprising crosslinked cation-binding polymers and their use Inactive 19-Jul-2012 000000000
GB-2519479-B Compositions comprising crosslinked cation-binding polymers Inactive 19-Jul-2012 A61K31/78 0
To view Relypsa’s complete patent history, request access »

Relypsa Executive Team (21)

Name Title Board Seat Contact Info
Wilhelm Stahl Ph.D Senior Vice President, Pharmaceutical Operations & Chief Technology Officer
You’re viewing 1 of 21 executive team members. Get the full list »

Relypsa Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Relypsa Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
Amgen Corporation Minority 000 0000 000000 0
Delphi Ventures Venture Capital Minority 000 0000 000000 0
Mediphase Venture Partners Venture Capital Minority 000 0000 000000 0
New Leaf Venture Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »